DIRS.INFO The most relevant business & tech news

☆ Kids made fun of my unusual name growing up. It shaped my personality, and I've embraced it.
▼ + stars: | 2024-11-20 | by ( Dixie Gillaspie | ) www.businessinsider.com time to read: +5 min

Growing up in Dixie, surrounded by more common names like Mary and Jane, made me who I am. Mary, Jane, or Ann would do nicely. AdvertisementIn the company of my peers a name like Dixie meant being teased, even tormented, with nowhere to hide. AdvertisementI've embraced my unusual nameKids weren't the only ones to think my name was an invitation to innuendo and amusement. AdvertisementI have to wonder if I would have developed a milder personality if Dad had his way and I'd ended up a Mary, Jane, or Ann.

Persons: Mary, Jane, David, Nobody, didn't, Ann, Dixie Diane, Dixie, Hey Dix, giggles, Richard, it's, I've, Badfinger, Dizzy Gillespie, Dad, I'd, Marys, Janes Locations: Dixie, Jennifers

☆ I didn't expect to become a 'trad wife,' but taking care of my husband eases my anxiety. I couldn't be happier in my marriage.
▼ + stars: | 2024-11-02 | by ( Hf Sylaj | ) www.businessinsider.com time to read: +4 min

Being a traditional wife means wanting the best for my husband. AdvertisementMy journey to becoming a "trad wife" — or traditional wife — started in 2012 when I made dinner for a man I barely knew. I also knew I wanted to be the kind of old-fashioned wife we now call a trad wife. AdvertisementTo me, a "trad wife" isn't about how many kids you have. Being a traditional wife means I am secure in my place in this world and in my marriage.

Persons: —, Hamburger, couldn't Organizations: Service Locations: Europe, Eastern Europe

☆ Haleon CEO Brian McNamara: We've seen double-digit growth in China
▼ + stars: | 2024-10-31 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Haleon CEO Brian McNamara: We've seen double-digit growth in ChinaHaleon CEO Brian McNamara joins 'Mad Money' host Jim Cramer to talk quarterly results, China growth, consumer trends and more.

Persons: Brian McNamara, We've, Jim Cramer Locations: China

☆ How activist Starboard may help boost value in Kenvue's skin and beauty business
▼ + stars: | 2024-10-26 | by ( Kenneth Squire | ) www.cnbc.com time to read: +8 min

The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Self Care product categories include pain care; cough cold allergy; and "other self care." The Skin Health and Beauty segment's product categories include face and body care and hair, sun and others. Skin Health and Beauty has been proven to be a marketing business whose growth can be greatly aided by social media. Kenvue has a solid business with iconic brands and one underperforming segment in Skin Health and Beauty.

Persons: Russell, Johnson, Kenvue, Michael CeraVe, Ken Squire Organizations: Skin, Health, Self, pharma, Colgate, Palmolive, Haleon, Kenvue, Essential Health, L'Oreal, Beauty, Skin Health, Management, 13D Locations: North America, Asia, Europe, Middle East, Africa, America, CY19, CeraVe

Kenvue CEO Thibaut Mongon at the New York Stock Exchange for its initial public offering, May 4, 2023. Activist investor Starboard Value has a large stake in Kenvue , which spun out of Johnson & Johnson in mid-2023, according to people familiar with the matter. Starboard's push at Kenvue comes just two weeks after news broke it had amassed a roughly $1 billion stake in struggling pharmaceutical company Pfizer. Johnson & Johnson completed its separation from Kenvue in August last year, though the pharmaceutical giant still holds a stake in the new company. Kenvue started trading on the New York Stock Exchange in May 2023, ending its first day of trading with a share price of about $27.

Persons: Thibaut Mongon, Johnson, Starboard's Jeff Smith, J's, Haleon, Kenvue Organizations: New York Stock Exchange, CNBC, Wall Street, Pfizer, Johnson, J, Procter Locations: Kenvue

☆ A learning mindset is critical for success says Haleon's US CMO Katie Williams
▼ + stars: | 2024-06-24 | by ( Julia Hood | ) www.businessinsider.com time to read: 1 min

Link icon An image of a chain link. It symobilizes a website link url. Link icon An image of a chain link. Copy LinkTwitter LinkedIn icon LinkedIn Link icon An image of a chain link. Twitter LinkedIn icon LinkedIn Link icon An image of a chain link.

☆ Haleon CEO: Expect to see volume growth in 2024
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHaleon CEO: Expect to see volume growth in 2024Brian McNamara, CEO of Haleon, joins to discuss the firm's earnings. The consumer health company says it expects the operating environment to remain challenging, but is eyeing up to 6% organic revenue growth this year.

Persons: Brian McNamara

WASHINGTON (AP) — The maker of Robitussin cough syrup is recalling several lots of products containing honey due to contamination that could pose a serious risk to people with weakened immune systems. Haleon’s recall covers eight lots of Robitussin Honey CF Max Day Adult and Robitussin Honey CF Max Nighttime Adult, which were distributed to stores and pharmacy suppliers. The products have the potential to cause “severe or life-threatening adverse events,” if taken by people with weakened immune systems, such as organ transplant recipients or those with HIV. Several million people in the U.S. have conditions that impair the immune system's ability to fight off infections. Haleon did not disclose the nature of the contamination but said use of the products could result in severe fungal infections.

Persons: Honey, Haleon Organizations: WASHINGTON, Max, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, New Jersey

☆ Lightning Round: I'd back Moderna here, says Jim Cramer
▼ + stars: | 2024-01-16 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: I'd back Moderna here, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Moderna, Haleon, Lockheed Martin and more.

Persons: Jim Cramer, Lockheed Martin Organizations: Moderna, Lockheed Locations: Moderna, Haleon

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ Jim Cramer compares consumer health companies Haleon and Kenvue
▼ + stars: | 2023-11-14 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Jim Cramer compares consumer health companies Haleon and Kenvue'Mad Money' host Jim Cramer takes a look at two consumer health companies, Haleon and Kenvue, to judge which stock is better for your portfolio.

Persons: Jim Cramer, Kenvue

☆ Haleon CEO Brian McNamara sits down with Jim Cramer
▼ + stars: | 2023-11-03 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Haleon CEO Brian McNamara sits down with Jim CramerHaleon CEO Brian McNamara sits down with 'Mad Money' host Jim Cramer to talk quarterly earnings, the consumer healthcare industry, consumer trends and more.

Persons: Brian McNamara, Jim Cramer

☆ Advil maker Haleon misses revenue estimates as North America demand drags
▼ + stars: | 2023-11-02 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies Haleon Plc FollowGSK plc FollowNov 2 (Reuters) - Haleon (HLN.L) missed market estimates for third-quarter revenue on Thursday, as the world's largest consumer healthcare firm grappled with weak demand for its painkillers, digestive health and vitamin supplements in North America. For the three months ended Sept. 30, Haleon reported a 5% organic increase in revenue to 2.79 billion pounds ($3.40 billion), but it came slightly below analysts' expectations of 2.83 billion pounds, according to a company-compiled consensus. The company said overall volumes for the quarter declined by 1.6%, while North America revenues fell 7.5% on a reported basis. Haleon, which was carved out of British drugmaker GSK (GSK.L) last year, has been raising prices to offset high costs. ($1 = 0.8215 pounds)Reporting by Eva Mathews in Bengaluru; Editing by Rashmi Aich and Gerry DoyleOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Haleon, Eva Mathews, Rashmi Aich, Gerry Doyle Organizations: New York Stock Exchange, REUTERS, GSK, Consumer, Thomson Locations: New York City, U.S, North America, British, Bengaluru

☆ Sanofi loses $21 bln in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( Ludwig Burger | ) www.reuters.com time to read: +6 min

Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability". EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target. CONSUMER STAND-ALONECEO Hudson said the core innovative drugs business had improved enough to soon do without the more predictable cash flows from consumer products. The logo of French drugmaker Sanofi is seen a the Sanofi Genzyme Polyclonals in Lyon, France, September 30, 2023. The timing of the potential consumer listing, which Sanofi said would be in the fourth quarter of 2024 or later, would be set to maximize shareholder value.

Persons: Hudson, Sanofi, drugmaker, Paul Hudson, Terence McManus, Johnson, we've, Gonzalo Fuentes, Roche, Dupixent, Ludwig Burger, Sherry Jacob, Phillips, Mark Potter, Sharon Singleton Organizations: Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer, Bayer, Polyclonals, REUTERS, Provention, Merck & Co, Thomson Locations: France, Bellevue, Lyon, Paris

☆ Investors reject Sanofi's cure to sickly valuation
▼ + stars: | 2023-10-27 | by ( ) www.reuters.com time to read: +3 min

LONDON, Oct 27 (Reuters Breakingviews) - Sanofi (SASY.PA) investors dislike CEO Paul Hudson’s prescription to reinvigorate the pharmaceutical group’s weak valuation. Analysts polled by LSEG expect the division to hit an EBIT of 1.6 billion euros this year. On listed rival Haleon’s 15.6 times multiple, that business could be worth 25 billion euros. The rest of the Sanofi business may generate EBIT of 11.4 billion euros. The problem is that investors don’t appear to want to take the harsh medicine that leads to a cure.

Persons: Paul Hudson’s, Ernst & Young, Sanofi, EBIT, Roche, Karen Kwok, Francesco Guerrera, Streisand Neto Organizations: Reuters, Sanofi, Ernst, LSEG, Novartis, Novo Nordisk, GSK, AstraZeneca, X, Unilever, Thomson

☆ Sanofi loses $21 billion in market value after dropping 2025 profit target
▼ + stars: | 2023-10-27 | by ( ) www.cnbc.com time to read: +2 min

Chesnot | Getty ImagesSanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business to focus on its core innovative drugs business. Under a push to spend more on immunology and inflammation drug development, the company abandoned a target for a 32% operating profit margin for 2025 to focus on "long-term profitability." Sanofi shares trade at a 12 month forward price-to-earnings ratio of 11, a discount to AstraZeneca's 16 and global pharma index of 17, according to LSEG data. Bayer, led by a new CEO since June, has faced calls by several investors to split off its consumer business. EPS would see a strong rebound in 2025 but not enough to sustain the previous margin target.

Persons: Sanofi, drugmaker, Paul Hudson, Terence McManus, Kenvue, Johnson, Bayer Organizations: Chesnot, Getty, Sanofi, Bellevue Asset Management, Reuters, Barclays, Johnson, GSK, Pfizer Locations: Gentilly, Paris, France, Bellevue

The trial for the Cantlay/Harper case, which was set to begin on Nov. 13, will now be dismissed, GSK said, adding it had also settled three remaining breast cancer cases in California related to the same drug. The latest settlements in California were related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. GSK did not admit any liability and said it would vigorously defend itself in any other Zantac cases. In June, GSK agreed to settle a similar lawsuit in California.

Persons: Harper, Brendan McDermid, Morgan, Jeffries, Zantac, Boehringer Ingelheim, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum, Louise Heavens, Emelia Organizations: pare, Citi, GSK, Reuters, REUTERS, Barclays, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Arexvy, California . California, Bengaluru, London

REUTERS/Brendan McDermid/Illustration/File Photo Acquire Licensing RightsOct 11 (Reuters) - GSK (GSK.L) on Wednesday said it would confidentially settle another lawsuit in California alleging its discontinued heartburn drug Zantac caused cancer, as the British drugmaker sought to end costly litigation. The latest settlements in California related to cases due to go to trial in November, with a further set scheduled to begin in Delaware courts in January, GSK said. The company still faces about 79,000 cases related to Zantac in the United States, with 73,000 of them in Delaware. Late in June, the company agreed to settle a similar lawsuit with California resident James Goetz who alleged he developed bladder cancer after taking Zantac. The settlement could be read that GSK sees a risk that these Zantac cases are strong enough that the company might lose at trial, J.P Morgan added.

Persons: Brendan McDermid, Morgan, Harper, Zantac, Boehringer Ingelheim, James Goetz, J.P Morgan, Eva Mathews, Maggie Fick, Nivedita Bhattacharjee, Bernadette Baum Organizations: REUTERS, GSK, Citi, J.P, Pfizer, Sanofi, FDA, Thomson Locations: California, British, Delaware, United States, Bengaluru, London

☆ GSK raises $1.1 billion from Haleon stake sale
▼ + stars: | 2023-10-06 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Dado Ruvic/Illustration Acquire Licensing RightsOct 6 (Reuters) - British drugmaker GSK (GSK.L) on Friday said it raised 885.6 million pounds ($1.08 billion) from a discounted stake sale in Haleon (HLN.L), cutting its shareholding to 7.4% in the world's largest standalone consumer healthcare firm. The sale of 270 million shares at 328 pence apiece, represented a discount of about 2.5% to Haleon's last close of 336.25 pence on Thursday. Shares in Haleon were down 1.2% while GSK was marginally up 0.4% at 0800 GMT. Pfizer, which holds a 32% stake in Haleon, said in May it plans to cut its ownership in a "slow and methodical" manner within months. The British drugmaker and Pfizer have agreed to not sell any further Haleon shares for 60 days from the settlement of placing.

Persons: Dado Ruvic, Emma Walmsley, Prerna Bedi, Sonia Cheema, Elaine Hardcastle Organizations: GSK, GlaxoSmithKline, REUTERS, British, AstraZeneca, London Stock Exchange, Pfizer, Thomson Locations: Haleon, British, Bengaluru

☆ Exclusive-Bayer investor Artisan calls for breakup of company
▼ + stars: | 2023-08-25 | by ( Richa Naidu | Ludwig Burger | ) www.reuters.com time to read: +4 min

Artisan wants the drugs-to-pesticides company to find new owners for its over-the-counter and pharmaceutical units, it said. Before taking over as CEO, Anderson said he was keeping an open mind on whether to break up the company. Artisan is Bayer’s 16th biggest investor, according to Refinitiv data. Samra said the chairman of Bayer’s supervisory board, Norbert Winkeljohann, has not directly written a letter back to Artisan, but said Artisan had “been in contact” with the company. Samra said Artisan “has not suggested specifically how (Bayer) should restructure their business” in the letter.

Persons: “, Wolfgang Rattay, Bill Anderson, Roche, Anderson, ” David Samra, Bayer, ” Samra, they’re, ” Bayer, Werner Baumann, Samra, Norbert Winkeljohann, China’s Syngenta, Johnson Organizations: Bayer, Artisan Partners, Reuters, Bayer AG, REUTERS, Bluebell Capital Partners, Artisan, Artisan’s, Science, pharma, Johnson, GSK Locations: Leverkusen, Germany, Swiss

☆ Zero-day-options, weak technicals and China: Breaking down the market’s August headwinds
▼ + stars: | 2023-08-17 | by ( Fred Imbert | ) www.cnbc.com time to read: +4 min

"The S & P is not quite there, but we would be very surprised if it doesn't follow the NDX's lead." On top of that, some are worried that another real estate crisis in China may be brewing. "It's been almost two years since China Evergrande Group, once China's largest real estate developer, shocked the financial markets by defaulting on $340 billion in debt. Since then, the Chinese real estate market has been in a serious slump," wrote Ed Yardeni of Yardeni Research. Investment in real estate fell 8.5% y/y during the first seven months of this year."

Persons: Goldman Sachs, Scott Rubner, Rubner, 0DTE, Technicals, Wolfe, Rob Ginsberg, Ginsberg, It's, Ed Yardeni, we're, Sarat Sethi, Johnson, Sethi, CNBC's, — CNBC's Michael Bloom Organizations: Wolfe Research, Nasdaq, China Evergrande Group, Yardeni, Investment, U.S, JPMorgan Locations: China, U.S, Freeport, McMoRan, Haleon

☆ Investor Sarat Sethi says don’t chase this rally, but you can buy these safe stocks
▼ + stars: | 2023-08-10 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

Chasing the market higher is a bad idea right now, and investors should turn to safe-haven sectors instead, investor Sarat Sethi warned. "I think as an equity investor, one needs to be really careful here and not chase some of these rallies, especially for stocks that are looking for lower discount rates." Stocks rose on the back of the data, with the Dow Jones Industrial Average trading more than 400 points higher at its session peak. Haleon and pharmaceutical giant Johnson & Johnson were also mentioned by Sethi. Johnson & Johnson is down 2% in 2023 but has risen more than 3% in August.

Persons: Sarat Sethi, Sethi, Dow Jones, Freeport's, Johnson Organizations: Reserve, Dow Jones Industrial, Johnson, GSK, Janssen Pharmaceuticals, Food and Drug Administration Locations: Freeport, McMoRan

☆ GSK Nigeria calls an end to its business, to return cash
▼ + stars: | 2023-08-03 | by ( Chijioke Ohuocha | ) www.reuters.com time to read: +2 min

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria (GLAXOSM.LG) said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods. GSK Nigeria, which has faced increased competition from local companies and imports from India and China, said its half-year sales had dropped to 7.75 billion naira ($9.82 million), from 14.8 billion naira in the same period a year ago. GSK Nigeria said it is working with advisers to agree next steps and plans to submit a scheme of arrangement to Nigeria's Securities and Exchange Commission, which if approved will see it return cash to shareholders except its parent GSK. "For the above reasons, and having, together with GSK UK, evaluated various other options, the Board of GlaxoSmithKline Consumer Nigeria Plc has concluded that there is no alternative but to cease operations," GSK Nigeria said in a statement. Shares in GSK Nigeria, in which British drugmaker GSK has a 46.4% stake and Nigerian shareholders the remaining 53.6%, closed at 8.10 naira, down from a peak of 42.24 naira in 2014.

Persons: Bola Tinubu, Tinubu, Chijioke Ohuocha, Alexander Smith Organizations: GlaxoSmithKline, GSK, Nigeria's Securities, Exchange Commission, Haleon, GlaxoSmithKline Consumer Nigeria Plc, British, Thomson Locations: ABUJA, Nigeria, GSK Nigeria, India, China, British, Africa

GSK reckons the spin-off has allowed the company to sharpen its focus on vaccines and infectious diseases and with $7 billion generated by the Haleon spin-off, it can fund deals to bolster a lacklustre drug pipeline. The company also reported an adjusted profit of 38.8 pence per share for the quarter, on sales of about 7.18 billion pounds ($9.26 billion). Analysts were expecting a profit of 34.7 pence per share on sales of about 6.77 billion pounds, according to company-compiled consensus estimates. Sales of Shingrix, the company's top-selling drug, generated 880 million pounds, beating analyst estimates of 872 million pounds. Sales of HIV treatments generated 1.58 billion in the quarter, ahead of the company-compiled consensus of about 1.5 billion pounds in the quarter.

Persons: Zantac, Emma Walmsley, Walmsley, Markus Manns, Dani Saurymper, Maggie Fick, Radhika Anilkumar, Janane Venkatraman, Savio D'Souza, Josephine Mason Organizations: GSK, British, Analysts, U.S, Union Investment, Pacific Asset Management, Thomson Locations: London, Bengaluru

☆ J&J-spinoff Kenvue forecasts upbeat annual profit on strong self-care demand
▼ + stars: | 2023-07-20 | by ( ) www.reuters.com time to read: +2 min

Companies Kenvue Inc FollowNeutrogena Corporation FollowHaleon Plc Follow Show more companiesJuly 20 (Reuters) - Kenvue (KVUE.N), the former consumer health unit of Johnson & Johnson (JNJ.N), forecast full-year profit above Wall Street estimates on Thursday, betting on resilient demand for its skincare and self-care products such as Neutrogena and Tylenol. Kenvue, in its first results after being spun off from Johnson & Johnson in May, forecast full-year adjusted profit per share between $1.26 and $1.31. However, adjusted gross profit margin came in at 57.5%, compared to 59.3% a year earlier, dragged by a strong dollar and higher costs. Meanwhile, J&J raised its 2023 profit forecast on Thursday, banking on the strength in its medical devices business and demand for its cancer drugs such as Darzalex. Net sales rose 5.4% to $4.01 billion while adjusted profit per share came in at 32 cents.

Persons: Johnson, Haleon, J, Ananya Mariam Rajesh, Raghav, Devika Syamnath Organizations: Johnson, Wall, Thomson Locations: Bengaluru

Search resuls for: "Haleon"

25 mentions found